tiprankstipranks
Advertisement
Advertisement

BMRN Stock Latest News

BioMarin and n-Lorem Foundation enter research collaboration in ReNU syndrome
The FlyBioMarin and n-Lorem Foundation enter research collaboration in ReNU syndrome
2d ago
BMRN
BioMarin price target raised to $76 from $75 at Citi
PremiumThe Fly
BioMarin price target raised to $76 from $75 at Citi
13d ago
BMRN
Neutral Stance Maintained on BioMarin as Competitive Threats Offset VOXZOGO Progress; $50 Price Target Reaffirmed
PremiumRatings
Neutral Stance Maintained on BioMarin as Competitive Threats Offset VOXZOGO Progress; $50 Price Target Reaffirmed
15d ago
BMRN
BioMarin announces FDA accepts sNDA for full approval of Voxzogo
PremiumThe Fly
BioMarin announces FDA accepts sNDA for full approval of Voxzogo
16d ago
BMRN
BioMarin’s Gene Therapy Study in Tough Hemophilia A Patients Reaches Completion: What Investors Should Watch
PremiumCompany Announcements
BioMarin’s Gene Therapy Study in Tough Hemophilia A Patients Reaches Completion: What Investors Should Watch
19d ago
BMRN
BioMarin price target lowered to $62 from $66 at RBC Capital
PremiumThe FlyBioMarin price target lowered to $62 from $66 at RBC Capital
22d ago
BMRN
BioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability
Premium
Company Announcements
BioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability
1M ago
BMRN
BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia
Premium
The Fly
BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia
1M ago
BMRN
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
PremiumThe Fly
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
2M ago
ASND
BMRN
BioMarin Shareholders Approve 2026 Governance and Equity Plan
PremiumCompany Announcements
BioMarin Shareholders Approve 2026 Governance and Equity Plan
2M ago
8K
BMRN
Jason Gerberry Maintains Buy on BioMarin, Reiterates $80 Price Target Despite Voxzogo Patent Uncertainty
PremiumRatings
Jason Gerberry Maintains Buy on BioMarin, Reiterates $80 Price Target Despite Voxzogo Patent Uncertainty
2M ago
BMRN
3 Best Stocks to Buy This Week, According to Analysts – May 25-May 29
PremiumMarket News
3 Best Stocks to Buy This Week, According to Analysts – May 25-May 29
2M ago
BMRN
FUTU
BioMarin price target lowered to $111 from $116 at Canaccord
PremiumThe FlyBioMarin price target lowered to $111 from $116 at Canaccord
2M ago
BMRN
Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
2M ago
BMRN
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
Premium
The Fly
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
2M ago
BMRN
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
PremiumThe Fly
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
2M ago
AMT
BAP
BioMarin price target lowered to $80 from $85 at BofA
PremiumThe Fly
BioMarin price target lowered to $80 from $85 at BofA
2M ago
BMRN
BioMarin initiated with a Buy at Citi
PremiumThe Fly
BioMarin initiated with a Buy at Citi
2M ago
BMRN
BioMarin price target lowered to $62 from $64 at Leerink
PremiumThe Fly
BioMarin price target lowered to $62 from $64 at Leerink
2M ago
BMRN
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
PremiumThe FlyBioMarin price target lowered to $50 from $55 at H.C. Wainwright
2M ago
BMRN
BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
Premium
The Fly
BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
2M ago
BMRN
Morgan Stanley Sees the S&P 500 Hitting 8,300 – 2 Stocks It Says Could Surge Alongside It
Premium
Market News
Morgan Stanley Sees the S&P 500 Hitting 8,300 – 2 Stocks It Says Could Surge Alongside It
2M ago
ARXS
BMRN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >